GlobalRPh Clinical TechnologyBeyond LDL-C: Understanding Cardiovascular Risk With PREVENT, ApoB, Lp(a), Non-HDL-C and Advanced Lipid AnalysisIntroducing the GlobalRPh Cardiovascular Risk and Advanced Lipid Analyzer, a layered cardiovascular prevention tool that combines the standard lipid panel with advanced lipoprotein markers, derived calculations, kidney and metabolic context, coronary calcium, and the American
Tag: ApoB
Insulin Resistance in Non-Obese Patients: The “Metabolically Obese Normal Weight” Paradox
Insulin Resistance in Non-Obese Patients: The "Metabolically Obese Normal Weight” Paradox Review Abstract Normal body mass index (BMI) has long been used as a convenient and widely accepted screening tool for assessing overweight, obesity, and cardiometabolic risk. Although BMI remains valuable for population level surveillance and initial clinical
The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden
The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden Review Abstract Lipidology is undergoing a clinically important transition from traditional cholesterol-centered assessment toward a more precise evaluation of atherogenic lipoprotein burden. Low-density lipoprotein cholesterol (LDL-C) remains a validated therapeutic target
Cholesterol Guidelines 2025: Should Age 40 Be the New Threshold for Statin Therapy?
